• 1
    Link RE, Morton RA. Indications for pelvic lymphadenectomy in prostate cancer. Urol Clin North Am 2001; 28:4918
  • 2
    Siemens DR. Why all prostate cancer surgery should include an adequate lymph node dissection. Can Urol Assoc J 2010; 4:4279
  • 3
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341:17818
  • 4
    Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008; 101:15138
  • 5
    Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69:1095101
  • 6
    Nguyen PL, Chen MH, Hoffman KE, Katz MS, D'Amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 2009; 74:1049
  • 7
    Rahman S, Cosmatos H, Dave G, Williams S, Tome M. Predicting pelvic lymph node involvement in current-era prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82:90610.
  • 8
    Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 1998; 159:20239
  • 9
    Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:1104
  • 10
    Roach M, 3rd, Marquez C, Yuo HS et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28:337
  • 11
    Cagiannos I, Karakiewicz P, Eastham JA et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Uro. 2003; 170:1798803
  • 12
    Lattouf JB, Beri A, Jeschke S, Sega W, Leeb K, Janetschek G. Laparoscopic extended pelvic lymph node dissection for prostate cancer: description of the surgical technique and initial results. Eur Urol 2007; 52:134755
  • 13
    Pezzullo JC. Logistic Regression, Version 05.07.20. Available at: Accessed January 2012
  • 14
    Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome. Cancer 2006; 107:43950
  • 15
    Briganti A, Shariat SF, Chun FK et al. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. BJU Int 2007; 100:52832
  • 16
    O'Brien BA, Brown AL, Shannon T, Cohen RJ. Prostate biopsy in Western Australia 1998–2004. Prostate Cancer Prostatic Dis 2010; 13:2639
  • 17
    Briganti A, Karakiewicz PI, Chun FK et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 2007; 51:157381
  • 18
    Conrad S, Graefen M, Pichlmeier U et al. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 2002; 167:5215
  • 19
    Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59:6171